An Irish Biotech has been Granted a Key EU Patent for Fatty Livers

Irish clinical-stage Biotech company DS Biopharma is evolving in the chronic disease field and has been granted an European patent for the use of bioactive active pharmaceutical ingredient (API) DS102 (15-HEPE) for fatty liver disorders.

The concept of lipids acting as signaling and regulatory molecules is now taken for granted, although bioactive lipid technology is a recent field in the chronic disease spread. Specifically, the patent for API use in fatty liver disorders was granted to DS Biopharma to cover non-alcoholic fatty liver disorder (NAFLD) and non-alcoholic steatohepatitis (NASH). The granted patent provides exclusivity until 2033.

Applications with similar scope of protection are pending in the US and other key countries, but DS Biopharma continues to prosecute additional patent applications for DS102 in both Europe and the rest of the world. The Company maintains a strong intellectual property portfolio comprising over twenty patent families protecting its compounds and products under development. This is the seventh granted patent in the DS pharmaceutical portfolio. Tien Nghiem, Director of Product Development and Intellectual Property at DS, commented:


We are delighted to announce this important milestone in our advanced programme to develop an effective treatment for fatty liver diseases using an innovative bioactive lipid.”

Just south of Dublin (Ireland) Dignity Sciences currently has 3 compounds in or starting clinical development, and a range of additional compounds in pre-clinical development too. DS intends to add more bioactive lipids into the current portfolio in the coming years.


Non-alcoholic fatty liver disorder types and DS Biopharmas DS102 Pipeline (Left CC: usermeds / Right Source: DS Bipoharma)

The molecules in question are produced naturally in the human body in minute quantities. A key advantage of these naturally occurring, bioactive lipid compounds is that in many cases they offer clinical advantages over existing treatments with regard to toxicity, tolerability and efficacy.

This is therefore a great step for DS Biopharma’s slow but steady development towards commercialization.

Let's Continue The Conversation

Feel free to send us comments about this article to and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.